CClinicalTrials.gg
Active, not recruitingNCT03730454TEFUpdated Mar 10, 2025

Transanastomotic Tube for Proximal Esophageal Atresia With Distal Tracheoesophageal Fistula Repair

An interventional study of Transanastomotic Tube (5FR) and No Transanastomotic Tube in Esophageal Atresia and Tracheoesophageal Fistula, sponsored by Phoenix Children's Hospital. Active, not recruiting at 10 sites in United States. Open to participants aged Up to 6 Months. Per ClinicalTrials.gov, last updated 2025-03-10.

Sponsored by Phoenix Children's Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
142
Allocation
Randomized
Ages
Up to 6 Months
Sex
All
01

Study summary

This trial will compare the effectiveness of two common surgical practices for Type C esophageal atresia repair: esophageal atresia (EA) with distal tracheoesophageal fistula (TEF). Infants with EA/TEF requiring surgical intervention will be recruited. Subjects will be randomized to either repair with or without transanstomotic tube (TT) during esophageal anastomosis creation. Primary outcome is symptomatic anastomotic stricture development requiring dilation within 12 months.

Read the detailed description

Esophageal atresia is a congenital condition requiring surgical intervention. The most common configuration is Gross type C, proximal EA with distal TEF (EA/TEF). The operation for type C includes tracheoesophageal fistula closure and esophageal anastomosis creation. Although mortality has markedly decreased since the operation was first described, overall complication rate remains at 62%, with the most common complication being anastomotic stricture, 43%.

During the creation of esophageal anastomosis, two common practices are to either use or not use a transanastomtic tube (TT) across the anastomosis. However the utility and benefits of TT have not been validated. A recent retrospective analysis by the Midwestern Pediatric Surgical Research Consortium identified anastomotic stricture to be the most common postoperative complications (43%). On univariate analysis, only utilization of a TT was significantly associated with strictures (p=0.013). On multivariate analysis after adjusting for both pre and perioperative variables, TT use remained significant with an odd ratio (OR) of 1.91 (p=0.04).

Given the inherent limitations and biases of retrospective analysis, there is a critical need for a prospective multi-institutional study to validate this finding. The Western Pediatric Surgical Research Consortium (WPSRC) consists of 10 children's hospitals including Phoenix Children's Hospital, Doernbecher Children's Hospital, Primary Children's Hospital, Lucile Packard Children's Hospital, Seattle Children's Hospital, Colorado Children's Hospital, Children's Hospital of Los Angeles, Rady Children's Hospital, Benioff Children's Hospital, and Children's Medical Center Dallas. The WPSRC will conduct a prospective randomized control trial comparing the effects of TT use. Target enrollment is 150. One group of patients will receive TTs and another group of patients will not receive TTs. We hypothesize that the use of TT will result in increased anastomotic stricture formation. Primary outcome is symptomatic anastomotic stricture requiring dilation within 12 months.

02

Conditions studied

  • Esophageal Atresia
  • Tracheoesophageal Fistula
03

Who can participate

Ages eligible
Up to 6 Months
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Infants diagnosed with type C esophageal atresia: proximal esophageal atresia and distal tracheoesophageal fistula
  • Primary repair of the esophageal atresia within the first six months of life
  • Minimum follow up of 1 year (12 months)

Exclusion criteria

Exclusion Criteria:

  • Other types of esophageal atresia without esophageal anastomosis creation
  • Major anomaly that influences likelihood of developing primary outcome or affects surgical treatment considerations
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
142 participants (actual)

Study arms

  • Experimental
    Group A. Transanastomotic Tube

    Group A. Transanastomotic Tube: Standard repair of EA/TEF will be performed. TT will be used during the esophageal anastomosis creation.

    Device: Transanastomotic Tube (5FR)

  • Experimental
    Group B. No Transanastomotic Tube

    Group B. No Transanastomotic tube group: Standard repair of EA/TEF will be performed. TT will NOT be used during the esophageal anastomosis creation.

    Other: No Transanastomotic Tube

Interventions

  • DeviceTransanastomotic Tube (5FR)

    5FR tube left in place for 5 days after completion of esophageal anastomosis.

  • OtherNo Transanastomotic Tube

    No transanastomotic tube used during repair

05

What researchers measure

Primary outcomes

  1. Anastomotic stricture

    Symptomatic anastomotic stricture requiring dilation

    Time frame: 12 months

Secondary outcomes

  1. Anastomotic Leak

    Anastomotic leak seen radiographically or in the operating room

    Time frame: 12 months

  2. Recurrent Fistula

    Recurrent fistula seen radiographically or in the operating room

    Time frame: 12 months

  3. Vocal cord injury

    vocal cord injury seen radiographically or in the operating room

    Time frame: 12 months

  4. Unplanned return to OR

    Any unplanned return to opearting room

    Time frame: 12 months

  5. Duration of perenteral nutrition

    Days requrining TPN

    Time frame: 12 months

  6. Length of Stay

    Length of stay during hospitalization for primary repair

    Time frame: 12 months

06

Study locations

10 sites
  • Phoenix Children's Hospital
    Phoenix, Arizona 85016, United States
  • Children's Hospital Los Angeles
    Los Angeles, California 90027, United States
  • Rady Children's Hospital
    San Diego, California 92123, United States
  • Benioff Children's Hospital
    San Francisco, California 94158, United States
  • Lucile Packard Children's Hospital
    Stanford, California 94305, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Doernbecher Children's Hospital
    Portland, Oregon 97239, United States
  • Children's Medical Center
    Dallas, Texas 75235, United States
  • Primary Children's Hospital
    Salt Lake City, Utah 84113, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
07

References and documents

Study documents

  • Protocol and statistical analysis plan · Dec 19, 2023

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT03730454
Lead sponsor
Phoenix Children's Hospital
Responsible party
Justin Lee, MD (Pediatric Surgeon, Phoenix Children's Hospital) — Principal investigator
First posted
Nov 5, 2018
Start date
May 11, 2018
Primary completion
Feb 28, 2025
Completion
Feb 28, 2026 (estimated)
Last update
Mar 10, 2025

Study contacts

Justin Lee, MD
principal investigator · Phoenix Children's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion